Novo Nordisk Q3 2026 results show Wegovy pill sales of DKK 5,394 million, adjusted operating profit up 27% at constant exchange rates, and a raised 2026 outlook. The report also covers CagriSema data, DKK 8.7 billion of impairments and a CFO change.
Pfizer Q3 2026 Results show $16.6 billion in revenue, 32% operational growth from launched and acquired products, and a raised 2026 outlook of $62.0–$64.0 billion. Pfizer also named Cecile Guegan as CFO and reported progress for Elrexfio, Litfulo, Talzenna and Tukysa.
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology led growth, the company reconfirmed FY2026 guidance, and it reported 12 positive Phase III programme readouts.
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase.
Novartis Q3 2026 results show net sales of USD 14.5 billion (+4%) and core operating income up 11%. The company raised its full-year core operating income guidance despite a USD 1.9 billion del-desiran impairment.
IQVIA Q3 2026 Results show revenue of $4,428 million, adjusted diluted EPS of $3.34, $3.2 billion in R&D Solutions net new bookings and raised full-year 2026 guidance.
Abbott Q3 2026 Results show net sales of $13.013 billion, up 14.5% reported and 7.0% comparable, with adjusted EPS of $1.42 and full-year EPS guidance tightened to $5.50 to $5.55.
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.
ohnson & Johnson Q3 2026 Results: sales rose 5.9% to $25.4B, adjusted EPS hit $2.59 and 2026 guidance rose to $11.10 adjusted EPS at the midpoint.
Charles River Laboratories (NYSE: CRL) posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, then raised full-year guidance on strengthening DSA demand and Manufacturing outperformance, even as GAAP results absorbed a one-time loss from its CDMO and Cell Solutions divestiture.
